

# Technology Licensing Opportunity

Non-Confidential Summary



Industry  
Liaison  
Office

## VACCINE AGAINST INCLUSION BODY HEPATITIS ROI# 09-009

### ***Opportunity:***

Researchers at the University of Saskatchewan have produced a novel vaccine against inclusion body hepatitis in broiler chickens. No live vaccine against a wide range of adenoviral strains is currently available.

### ***Background:***

Inclusion body hepatitis is the most prevalent infectious disease affecting the poultry industry in Canada (*Gomis S. et al, 2006*) and is an emerging problem worldwide. In Canada, the annual direct costs associated with this disease are estimated at over \$10 million.

Inclusion body hepatitis is caused by fowl adenovirus (FAdV) and lasts 7-14 days with a mortality rate of 5-30%. FAdV infection affects chickens from 10 days to 6 weeks old.

### ***Vaccine benefits:***

- Superior protection of parents and progeny against a range of adenoviral strains, including homologous and heterologous strains,
- Composed of FAdV-2, FAdV-7, FAdV-8a/8b or FAdV-11 serotype strains
- Efficient and easy delivery routes, including “water supplementation”



Industry Liaison Office  
15 Innovation Boulevard, Suite 250  
Saskatoon, SK, S7N 2X8  
Tel: (306) 966-1465

# Technology Licensing Opportunity

Non-Confidential Summary



Industry  
Liaison  
Office

## LIVE VACCINE AGAINST INCLUSION BODY HEPATITIS ROI# 09-009

### ***Researcher profile:***

#### **Dr. Susantha Gomis**

Professor, Dept. of Veterinary Pathology, WCVMM

Research interests: basic and applied aspects of pathogenesis and control of viral and bacterial diseases in poultry and mammalian species.

### ***Patent Status:***

US patent application no. 12/969,444

CA patent application no. 2,725,435

### ***Publications:***

1. Gomis S, Goodhope R, Ojkic D, and Wilson P. Inclusion Body Hepatitis as a Primary Disease in Broilers in Saskatchewan. Canada Avian Diseases, 50(4):550-555 (2006).
2. Ojkic D, Martin E, Swinton J, Vaillancourt JP, Boulianne M, and Gomis S. Genotyping of Canadian isolates of fowl adenoviruses. Avian Pathol. 37(1): 95-100 (2008b).

### ***Development Stage:***

Product is ready for licensing to a commercial partner.

### ***For more information, please contact:***

Oksana Akhova, PhD, MBA

Tel. (306) 966 5496

[oksana.akhova@usask.ca](mailto:oksana.akhova@usask.ca)

Industry Liaison Office  
15 Innovation Boulevard, Suite 250  
Saskatoon, SK, S7N 2X8  
Tel: (306) 966-1465